Lactoferrin inhibits platelet production from human megakaryocytes in vitro

Kuniko Matsumura-Takeda1, Tatsuhiro Ishida, Shinji Sogo

  • 1Department of Pharmacokinetics and Biopharmaceutics, Subdivision of Biopharmaceutical Sciences, Institute of Health Biosciences, The University of Tokushima, 1-78-1 Sho-machi, Tokushima 770-8505, Japan. kuniko_m_t@research.otsuka.co.jp

Insights

Human lactoferrin (hLF) inhibits platelet production from mature megakaryocytes by up to 60%. This study found hLF does not affect megakaryopoiesis, including cell proliferation and maturation.

Area of Science:

  • Hematology
  • Cell Biology

Background:

  • Megakaryopoiesis, proplatelet formation (PPF), and platelet (PLT) production mechanisms remain incompletely understood.
  • Lactoferrin (LF) exhibits diverse biological functions, including roles in cell proliferation and differentiation, with its receptor expressed on megakaryocytic cells.

Purpose of the Study:

  • To investigate the effect of human lactoferrin (hLF) on platelet production from primary human megakaryocytes (MKs).

Main Methods:

  • A system for PLT production from human CD34+ cells stimulated by thrombopoietin (TPO) was established.
  • TPO-induced CD34+ cells on day 5, showing increased proplatelets, PLTs, and CD41+ MKs, were used to examine hLF's effects.
  • hLF was applied in concentrations ranging from 3-30 µg/ml.

Main Results:

  • hLF significantly inhibited PLT production by approximately 60% within the tested concentration range.
  • hLF did not significantly alter CD41 expression intensity or ploidy in MKs.
  • hLF did not inhibit MK progenitors, indicating no impact on early megakaryopoiesis.

Conclusions:

  • hLF directly inhibits platelet production from mature megakaryocytes.
  • hLF does not inhibit megakaryopoiesis, including the proliferation and maturation stages of MK development.